The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“Furthermore, the expression and activity of many key enzymes involved in de novo fatty acid synthesis, such as ATP citrate lyase (ACLY), acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN), are up-regulated and associated with poor clinical outcomes in many types of cancers[3-5].”
BackgroundCellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123 · cited 1×
“Continuous de novo lipogenesis provides cancer cells with membrane building blocks, signaling lipid molecules and posttranslational modifications of proteins to support rapid cell proliferation[1, 2].”
BackgroundSREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413
Calvisi, D. F., Wang, C., Ho, C., Ladu, S., Lee, S. A., Mattu, S., Destefanis, G., Delogu, S., Zimmermann, A., Ericsson, J., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.12.006 · Cited by 595
De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy
Mashima, T., Seimiya, H., & Tsuruo, T. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605007 · Cited by 555
Modulation of PPAR activity via phosphorylation
BURNS, K., & VANDENHEUVEL, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.018 · Cited by 443
Huang, D., Li, T., Li, X., Zhang, L., Sun, L., He, X., Zhong, X., Jia, D., Song, L., Semenza, G. L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.028 · Cited by 352 · cited 3×
“Huang et al. has also provided additional lines of evidence that HIF-1-mediated suppression of FAO is critical for the growth of HCC cells[37].”
BackgroundTargeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Guo, D., Bell, E., Mischel, P., & Chakravarti, A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990486 · Cited by 323
Transcriptional Control of Hepatic Lipid Metabolism by SREBP and ChREBP
Xu, X., So, J.-S., Park, J.-G., & Lee, A.-H. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358523 · Cited by 308
Yoshikawa, T., Ide, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Matsuzaka, T., Yatoh, S., Kitamine, T., Okazaki, H., Tamura, Y., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0190 · Cited by 297
EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair
Gabison, E. E., Hoang-Xuan, T., Mauviel, A., & Menashi, S. (2005) · Biochimie · doi:10.1016/j.biochi.2004.09.023 · Cited by 285
Tumor Metabolism of Lactate: The Influence and Therapeutic Potential for MCT and CD147 Regulation
Kennedy, K. M., & Dewhirst, M. W. (2010) · Future Oncology · doi:10.2217/fon.09.145 · Cited by 280
Latruffe, N., & Vamecq, J. (1997) · Biochimie · doi:10.1016/s0300-9084(97)81496-4 · Cited by 237
Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor
Ookhtens, M., Kannan, R., Lyon, I., & Baker, N. (1984) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1984.247.1.r146 · Cited by 199
Xu, J., Shen, Z.-Y., Chen, X.-G., Zhang, Q., Bian, H.-J., Zhu, P., Xu, H.-Y., Song, F., Yang, X.-M., Mi, L., et al. (2007) · Hepatology · doi:10.1002/hep.21465 · Cited by 183
Self-citationPPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism
BOCHER, V., PINEDA‐TORRA, I., FRUCHART, J., & STAELS, B. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04258.x · Cited by 178
ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment
Khwairakpam, A., Shyamananda, M., Sailo, B., Rathnakaram, S., Padmavathi, G., Kotoky, J., & Kunnumakkara, A. (2015) · Current Drug Targets · doi:10.2174/1389450115666141224125117 · Cited by 173
Lim, M., Martinez, T., Jablons, D. M., Cameron, R., Guo, H., Toole, B. P., Li, J., & Basbaum, C. B. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01474-4 · Cited by 171
Self-citationCancer-related issues of CD147.
Weidle, U. H., Scheuer, W., Eggle, D., Klostermann, S., & Stockinger, H. S. J. (2010) · PubMed · Cited by 169
Louie, S. M., Roberts, L. S., Mulvihill, M. M., Luo, K., & Nomura, D. K. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.07.008 · Cited by 168
Huang, Q., Li, J., Xing, J., Li, W., Li, H., Ke, X., Zhang, J., Ren, T., Shang, Y., Yang, H., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.035 · Cited by 158
Self-citationGrabacka, M., Plonka, P. M., Urbańska, K., & Reiss, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2556 · Cited by 154
MAPK- Kinases as Nucleo-Cytoplasmic Shuttles for PPARγ
Burgermeister, E., & Seger, R. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4453 · Cited by 152
Keung, W., Ussher, J. R., Jaswal, J. S., Raubenheimer, M., Lam, V. H., Wagg, C. S., & Lopaschuk, G. D. (2012) · Diabetes · doi:10.2337/db12-0259 · Cited by 142
Su, J., Chen, X., & Kanekura, T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.07.034 · Cited by 131
Yamauchi, Y., Furukawa, K., Hamamura, K., & Furukawa, K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4108 · Cited by 124
Kong, L., Liao, C., Fei, F., Guo, X., Xing, J., & Chen, Z. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01554.x · Cited by 111
Self-citationHuang, J., Viswakarma, N., Yu, S., Jia, Y., Bai, L., Vluggens, A., Cherkaoui‐Malki, M., Khan, M., Singh, I., Yang, G., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.030 · Cited by 106
Venkatesan, B. A., Valente, A. J., Prabhu, S. D., Shanmugam, P., Delafontaine, P., & Chandrasekar, B. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.05.007 · Cited by 104
Acetyl-CoA carboxylase-a as a novel target for cancer therapy
Cao, D. (2009) · Frontiers in Bioscience-Scholar · doi:10.2741/s82 · Cited by 103
PPARγ agonists inhibit growth and expansion of CD133+ brain tumour stem cells
Chearwae, W., & Bright, J. J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604786 · Cited by 93
Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma
Wu, J.-M., Skill, N. J., & Maluccio, M. A. (2010) · HPB · doi:10.1111/j.1477-2574.2010.00207.x · Cited by 79
König, B., Koch, A. H., Spielmann, J., Hilgenfeld, C., Hirche, F., Stangl, G. I., & Eder, K. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.01.009 · Cited by 75
Li, Y., Wu, J., Song, F., Tang, J., Wang, S.-J., Yu, X., Chen, Z., & Jiang, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277699 · Cited by 71
Self-citationHase, T., Yoshimura, R., Mitsuhashi, M., Segawa, Y., Kawahito, Y., Wada, S., Nakatani, T., & Sano, H. (2002) · Urology · doi:10.1016/s0090-4295(02)01747-8 · Cited by 65
Xu, T., Zhou, M., Peng, L., Kong, S., Miao, R., Shi, Y., Sheng, H., & Li, L. (2014) · Europe PMC (PubMed Central) · Cited by 60
Setoyama, D., Fujimura, Y., & Miura, D. (2013) · Genes to Cells · doi:10.1111/gtc.12098 · Cited by 60
Fei, F., Li, X., Xu, L., Li, D., Zhang, Z., Guo, X., Yang, H., Chen, Z., & Xing, J. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3816-1 · Cited by 58
Self-citationThe PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver
Borbath, I., Leclercq, I., Moulin, P., Sempoux, C. L., & Horsmans, Y. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.05.005 · Cited by 46
Cited by
The metabolism of cancer cells during metastasis
Bergers, G., & Fendt, S.-M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00320-2 · Cited by 950
Lipid droplets: platforms with multiple functions in cancer hallmarks
Cruz, A. L. S., Barreto, E. D. A., Fazolini, N. P. B., Viola, J. P. B., & Bozza, P. T. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2297-3 · Cited by 535
Lipid metabolism in cancer progression and therapeutic strategies
Fu, Y., Zou, T., Shen, X., Nelson, P. J., Li, J., Wu, C., Yang, J., Zheng, Y., Bruns, C., Zhao, Y., et al. (2021) · MedComm · doi:10.1002/mco2.27 · Cited by 393
Self-citationThe Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
Tian, L.-Y., Smit, D. J., & Jücker, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032652 · Cited by 329
Jiang, C., Zhu, Y., Chen, H., Lin, J., Xie, R., Li, W., Xue, J., Chen, L., Chen, X., & Xu, S. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06181-5 · Cited by 36
Metadata
- Authors
- Li, J., Huang, Q., Long, X., Zhang, J., Huang, X., Aa, J., Yang, H., Chen, Z., & Xing, J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 63
- Issue
- 6
- Pages
- 1378-1389
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1983457010
- Cited by
- 256
- References
- 40
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.